2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.01 The Actual Status of Biomarker Testing and Prognosis in Postoperative Recurrent NSCLC: Subgroup Analyses of WJOG15421L (REVEAL)

EP.06B.01 The Actual Status of Biomarker Testing and Prognosis in Postoperative Recurrent NSCLC: Subgroup Analyses of WJOG15421L (REVEAL)

Back to course

Pdf Summary

The document summarizes a subgroup analysis of the WJOG15421L study, focusing on biomarker testing and prognosis in patients with postoperative recurrent non-small cell lung cancer (NSCLC). The study highlighted the insufficient implementation of multigene testing in these recurrence cases. The analysis included 229 postoperative recurrent NSCLC cases from a pool of 1500 patients registered across 29 hospitals in Japan. The study underscored that patients with postoperative recurrence demonstrated a more favorable prognosis compared to those with advanced-stage NSCLC.<br /><br />Despite the crucial role of biomarker testing for personalized treatment strategies in the perioperative setting, its adoption remains limited. The study found that performing multigene testing is necessary for determining effective treatment strategies and drug selection. The results emphasize the need to integrate comprehensive biomarker testing early in the diagnosis of resectable NSCLC to prepare for the personalized medicine era.<br /><br />The study delineates its findings with various data visualizations that present implementation rates of genetic biomarker testing, success rates of OncomineTM DxTT testing based on specimen types and recurrence, and overall survival outcomes based on the recurrence type. Univariate and multivariate analyses highlighted factors such as age, sex, histological type, Eastern Cooperative Oncology Group Performance Status, smoking status, and comorbidities, assessing their impact on multigene testing and prognosis.<br /><br />Furthermore, the study included key criteria for inclusion, such as patients aged 20 and above with advanced or recurrent NSCLC diagnosed within a specified timeframe. Ultimately, the study calls for enhanced and timely implementation of multigene testing in medical practice to optimize treatment outcomes for NSCLC patients experiencing postoperative recurrence.

Asset Subtitle

Takayuki Takahama

Meta Tag

Speaker Takayuki Takahama

Topic Pathology and Biomarkers

Keywords

WJOG15421L study

biomarker testing

non-small cell lung cancer

NSCLC prognosis

multigene testing

postoperative recurrence

personalized treatment

genetic biomarker

OncomineTM DxTT

survival outcomes